Atika Capital Management’s Procept Biorobotics PRCT Stock Holding History

Atika Capital Management’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-57,000	Closed	-$1.87M	–	91
2023 Q3	$1.87M	Sell	57,000 -145,000	-72%	-$4.94M	0.25%	67
2023 Q2	$7.14M	Sell	202,000 -42,726	-17%	-$1.41M	0.71%	52
2023 Q1	$6.95M	Buy	244,726 +45,036	+23%	+$1.59M	1.03%	40
2022 Q4	$8.3M	Buy	199,690 +78,765	+65%	+$3.38M	1.19%	33
2022 Q3	$5.01M	Buy	120,925 +62,787	+108%	+$2.5M	0.43%	69
2022 Q2	$1.9M	Hold	58,138	–	–	0.21%	70
2022 Q1	$2.03M	Buy	+58,138	New	+$1.4M	0.17%	64

Other funds holding PRCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Atika Capital Management's PRCT Position: Q4 2023 in Review

Atika Capital Management sold out of Procept Biorobotics (PRCT) in Q4 2023, closing a stake of 57,000 shares — an estimated $1.87M sold.

Atika Capital Management first reported a position in PRCT in Q1 2022 and held it in 7 quarters. The position peaked at $8.3M in Q4 2022. 145 funds tracked by Wall St. Rank hold PRCT as of Q4 2023.

Atika Capital Management reported no remaining Procept Biorobotics position as of Q4 2023 after selling out during the quarter.
Atika Capital Management sold 57,000 Procept Biorobotics shares in Q4 2023, an estimated $1.87M.
Atika Capital Management first reported a position in Procept Biorobotics in Q1 2022 and held it in 7 quarters.
Atika Capital Management's Procept Biorobotics position peaked at $8.3M in Q4 2022.
145 funds tracked by Wall St. Rank held Procept Biorobotics as of Q4 2023.

Based on Atika Capital Management's 13F filing for Q4 2023, filed 13 Feb 2024.